Carmell Therapeutics (CTCX) Stock Analysis

What Carmell Therapeutics does

Carmell Therapeutics Corporation (CTCX) specializes in the creation of plasma-based bioactive materials (PBMs) aimed at catalyzing tissue regeneration and repair following injury, illness, or the effects of aging. Their flagship product, CT-101, is a versatile accelerant with a dual focus. For orthopedic and dental applications, it's designed to enhance bone healing in cases such as tibia fractures, foot and ankle fusions, spinal fusions, and also serves as a dental bone graft substitute and bone void filler. Furthermore, CT-101 acts as a tissue healing accelerant, addressing conditions like androgenetic alopecia (pattern baldness) and persistent chronic wounds. Established in 2008, the company operates from its headquarters in Pittsburgh, Pennsylvania.

Key metrics

ETFs linked to CTCX

Broad-market and Healthcare sector ETFs an investor holding Carmell Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CTCX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Carmell Therapeutics?

Carmell Therapeutics trades under the ticker CTCX on NASDAQ.

Which exchange is CTCX listed on?

CTCX is listed on NASDAQ.

What sector does Carmell Therapeutics operate in?

Carmell Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CTCX in a portfolio?

PortView shows CTCX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.